Eli Lilly Expands Global Innovation Reach with New Research Centers in China

Expansion in China: Eli Lilly has opened two new research centers in Beijing, China:
the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. This expansion aims to accelerate drug development and clinical research in China.

Gateway Labs:
The Lilly Gateway Labs in Beijing will provide office space and research strategy guidance for domestic start-up biotechnology companies to help them develop new drugs. This is the second Gateway Labs outside the U.S., following a planned European branch in the U.K..

Innovation Hub:
The Eli Lilly China Medical Innovation Center will serve as a hub for Eli Lilly's research and development in China, focusing on medical innovations and breakthrough therapies through collaborations with scientific research bodies.

Investment and Impact:
Eli Lilly has invested significantly in China, including a recent $200 million expansion of its Suzhou plant to increase production of type 2 diabetes and obesity medications. The company has conducted approximately 80 clinical studies in China and has won permits for 40 drugs or new medical indications since 2018.

Global Expansion:
The new centers in Beijing are part of Eli Lilly's global expansion of its Gateway Labs model, which also includes locations in San Francisco, Boston, and a planned site in San Diego.